Block listing Interim Review

Summary by AI ^BETAClose X

Hikma Pharmaceuticals PLC reports the six-monthly return for its block listing as of October 1, 2025. The report pertains to the Hikma Pharmaceuticals PLC 2018 Management Incentive Plan and the 2014 Executive Incentive Plan. The period covered is from April 1, 2025, to September 30, 2025. The balance of unallotted securities under the schemes from the previous return was 311,430 ordinary shares of 10 pence. The block scheme has not been increased since the last return, with an increase of 0 ordinary shares of 10 pence. During the period, 0 ordinary shares of 10 pence were issued or allotted under the schemes. Consequently, the balance under the schemes not yet issued or allotted at the end of the period remains at 311,430 ordinary shares of 10 pence.

Disclaimer*

Hikma Pharmaceuticals Plc

01 October 2025

Hikma Pharmaceuticals PLC

Block Listing Six Monthly Return

Date: 1 October 2025

Name of applicant:	Hikma Pharmaceuticals PLC
Name of schemes:	Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")
Period of return	From:	1 April 2025	To:	30 September 2025
Balance of unallotted securities under scheme(s) from previous return:	311,430 Ordinary Shares of 10 pence
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0 Ordinary Shares of 10 pence
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	0 Ordinary Shares of 10 pence
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	311,430 Ordinary Shares of 10 pence

Name of contact:	Helen Middlemist
Telephone number of contact:	+44(0)20 7399 2760

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END